9-deoxy-delta-9-prostaglandin-d2 and 2-2-bis(4-glycidyloxyphenyl)propane

9-deoxy-delta-9-prostaglandin-d2 has been researched along with 2-2-bis(4-glycidyloxyphenyl)propane* in 2 studies

Other Studies

2 other study(ies) available for 9-deoxy-delta-9-prostaglandin-d2 and 2-2-bis(4-glycidyloxyphenyl)propane

ArticleYear
PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway.
    Cellular signalling, 2010, Volume: 22, Issue:3

    Embryonic stem (ES) cells are genetically normal, pluripotent cells, capable of self-renewal and multi-lineage differentiation. Leukemia inhibitory factor (LIF) is a growth factor that can maintain the pluripotency of mouse ES cells in culture. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor transcription factors that regulate growth and differentiation of many cell types. We have shown earlier that 15-Deoxy-(12,14)-Prostaglandin J2 (15d-PGJ2), a natural ligand for PPARgamma, inhibits LIF-induced proliferation of mouse ES cells in culture. In this study we demonstrate that the PPARgamma antagonist Bisphenol A diglycidyl ether (BADGE) and 2-Chloro-5-nitro-N-(4-pyridyl)benzamide (T0070907) reverse the inhibition of ES cell proliferation by PPARgamma agonists. Stable transfection of ES cells with a dominant negative PPARgamma1 mutant also reduced the inhibition of proliferation by PPARgamma agonists. While 15d-PGJ2 and ciglitazone-induced growth-arrest in ES cells by blocking LIF signaling, PPARgamma antagonists and dominant negative PPARgamma1 mutant reversed proliferation by restoring LIF-induced Tyk2-Stat3 signaling. These results suggest that PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway.

    Topics: Animals; Antineoplastic Agents; Benzamides; Benzhydryl Compounds; Cell Differentiation; Embryonic Stem Cells; Epoxy Compounds; Leukemia Inhibitory Factor; Mice; Phosphorylation; PPAR gamma; Prostaglandin D2; Pyridines; Signal Transduction; STAT3 Transcription Factor; TYK2 Kinase

2010
Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
    The journal of pain, 2008, Volume: 9, Issue:7

    In this report, we demonstrate the transcription, expression, and DNA-binding properties of the peroxisome proliferator-activated receptor (PPAR)-gamma subtype of the peroxisome proliferator-activated nuclear receptor family to the spinal cord with real-time PCR, Western blot, and electrophoretic mobility shift assay. To test the hypothesis that activation of spinal PPAR-gamma decreases nerve injury-induced allodynia, we intrathecally administered PPAR-gamma agonists and/or antagonists in rats after transection of the tibial and common peroneal branches of the sciatic nerve. Single injection of either a natural (15-deoxy-prostaglandin J2, 15d-PGJ2) or synthetic (rosiglitazone) PPAR-gamma agonist dose-dependently decreased mechanical and cold hypersensitivity. These effects were maximal at a dose of 100 microg and peaked at approximately 60 minutes after injection, a rapid time course suggestive of transcription-independent mechanisms of action. Concurrent administration of a PPAR-gamma antagonist (bisphenol A diglycidyl ether, BADGE) reversed the effects of 15d-PGJ2 and rosiglitazone, further indicating a receptor-mediated effect. In animals without nerve injury, rosiglitazone did not alter motor coordination, von Frey threshold, or withdrawal response to a cool stimulus. Intraperitoneal and intracerebroventricular administration of PPAR-gamma agonists (100 microg) did not decrease mechanical and cold hypersensitivity, arguing against effects subsequent to diffusion from the intrathecal space. We conclude that ligand-induced activation of spinal PPAR-gamma rapidly reverses nerve injury-induced mechanical allodynia. New or currently available drugs targeted at spinal PPAR-gamma may yield important therapeutic effects for the management of neuropathic pain.. PPAR-gamma receptor agonists such as rosiglitazone and pioglitazone are approved as insulin sensitizers by the United States Food and Drug Administration. We demonstrate PPAR-gamma expression in the spinal cord and report that activation of these receptors inhibits allodynia. BBB-permeant PPAR-gamma agonists may yield important therapeutic effects for the management of neuropathic pain.

    Topics: Animals; Behavior, Animal; Benzhydryl Compounds; Blotting, Western; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Epoxy Compounds; Gene Expression; Injections, Intraventricular; Injections, Spinal; Male; Motor Activity; Neuralgia; PPAR gamma; Prostaglandin D2; Protein Binding; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Sciatic Nerve; Spinal Cord; Thiazolidinediones

2008